Clinical Trials on Puheh%C3%A4iri%C3%B6t

Total 22 results

NovelMed Therapeutics

Not yet recruiting

Study of NM8074 in Adult C3 Glomerulopathy Patients

C3 Glomerulopathy
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Pierre Fabre Medicament
Eurotrials Brasil Consultores Cientificos Ltda

Withdrawn

EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS

Venous Disease Classification (CEAP): C2 or C3
Novartis Pharmaceuticals

Recruiting

Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

C3 Glomerulopathy

Spain, France, Germany, Switzerland, United States, Japan, Turkey, China, United Kingdom, Italy, Argentina, Brazil, Greece, Israel, Netherlands
Mario Negri Institute for Pharmacological Research
Alexion Pharmaceuticals

Completed

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

Italy
Region Skane

Recruiting

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis | Complement Abnormality

Sweden
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
ChemoCentryx
Medpace, Inc.

Completed

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (ACCOLADE)

C3 Glomerulopathy (C3G)

United States, Spain, France, Netherlands, Belgium, Canada, Denmark, Germany, Ireland, Italy, United Kingdom
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
AxioMed Spine Corporation

Unknown

Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease

Symptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7

Germany, Switzerland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
Apellis Pharmaceuticals, Inc.

Available

C3G/Primary IC-MPGN EAP

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States
Sohag University

Recruiting

Prevalence and Pathological Features of C3 Dominant Glomerulonephritis Among Egyptian Population

C3 Nephropathy

Egypt
Celldex Therapeutics

Terminated

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

C3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type II

United States
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, Australia, Austria, United Kingdom, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

IgA Nephropathy | C3 Glomerulopathy

New Zealand, Australia, Korea, Republic of, Thailand, Germany, United Kingdom, Georgia
Omeros Corporation

Unknown

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Lupus Nephritis | IgAN | C3 Glomerulopathy | MN

United States, Hong Kong
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Lupus Nephritis | IgA Nephropathy | Membranous Nephropathy | C3 Glomerulonephritis | Dense Deposit Disease

United States
Novartis Pharmaceuticals

Available

Managed Access Programs for LNP023, Iptacopan

Paroxysmal Nocturnal Hemoglobinuria (PNH) | C3 Glomerulopathy (C3G)
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom

Clinical Trials on Puheh%C3%A4iri%C3%B6t

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations